Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Interest Expenses (2020 - 2025)

Historic Interest Expenses for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $11.3 million.

  • Apellis Pharmaceuticals' Interest Expenses fell 999.84% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 2414.23%. This contributed to the annual value of $40.4 million for FY2024, which is 3654.37% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Interest Expenses stood at $11.3 million for Q3 2025, which was down 999.84% from $11.2 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Interest Expenses' 5-year high stood at $12.5 million during Q3 2024, with a 5-year trough of $2.3 million in Q3 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' median Interest Expenses value was $7.7 million (recorded in 2022), while the average stood at $7.9 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first tumbled by 7597.64% in 2021, then soared by 24631.9% in 2022.
  • Apellis Pharmaceuticals' Interest Expenses (Quarter) stood at $3.0 million in 2021, then surged by 156.39% to $7.7 million in 2022, then dropped by 4.34% to $7.4 million in 2023, then soared by 55.82% to $11.5 million in 2024, then dropped by 2.21% to $11.3 million in 2025.
  • Its last three reported values are $11.3 million in Q3 2025, $11.2 million for Q2 2025, and $11.0 million during Q1 2025.